Enlivex Therapeutics Ltd. (ENLV): Price and Financial Metrics
GET POWR RATINGS... FREE!
ENLV Stock Price Chart Interactive Chart >
ENLV Price/Volume Stats
| Current price | $4.38 | 52-week high | $8.64 |
| Prev. close | $4.43 | 52-week low | $3.62 |
| Day low | $4.32 | Volume | 25,245 |
| Day high | $4.47 | Avg. volume | 30,482 |
| 50-day MA | $4.28 | Dividend yield | N/A |
| 200-day MA | $4.61 | Market Cap | 80.64M |
Enlivex Therapeutics Ltd. (ENLV) Company Bio
Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patients. The company is also developing Allocetra for the prevention of complications associated with bone marrow transplantations and/or HSCT, and acute multiple organ failure. It also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Latest ENLV News From Around the Web
Below are the latest news stories about ENLIVEX THERAPEUTICS LTD that investors may wish to consider to help them evaluate ENLV as an investment opportunity.
Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid TumorsNes-Ziona, Israel, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that an independent Data and Safety Monitoring Board (DSMB) has completed its prespecified data review for the first cohort of patients in the Company’s ongoing Phase I/II cell therapy clinical trial of AllocetraTM in patients with advanced-stage solid tumors (clinicaltrials.gov Identifier: NCT05581719). The |
Enlivex gets French and Belgian regulatory nod to expand mid-stage sepsis trialEnlivex Therapeutics (ENLV) said it had got approval from French and Belgian regulatory agencies to expand its phase two sepsis trial into those countries. Read more here. |
Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and BelgiumNes-Ziona, Israel, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the French Agency for Food, Environmental and Occupational Health and Safety (ANSES) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have cleared the amended protocol of the Company’s Phase II trial evaluating Allocetra™ in patients with sepsis. The approved protocol, which prev |
EQS-News: A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical TrialEQS-News: Enlivex Therapeutics, Ltd. A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial 07.12.2022 / 14:40 CET/CEST The issuer is solely responsible for the content of this announcement. Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced |
EQS-News: Enlivex Therapeutics, Ltd.: A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical TrialEQS-News: Enlivex Therapeutics, Ltd. A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial 07.12.2022 / 14:40 CET/C… |
ENLV Price Returns
| 1-mo | 11.24% |
| 3-mo | 2.82% |
| 6-mo | -13.61% |
| 1-year | -17.98% |
| 3-year | -45.11% |
| 5-year | -81.44% |
| YTD | 11.24% |
| 2022 | -37.00% |
| 2021 | -25.86% |
| 2020 | 0.46% |
| 2019 | 36.22% |
| 2018 | -66.38% |
Loading social stream, please wait...